Non-immunologic vascular failure of the transplanted heart

Journal of Heart and Lung Transplantation

Volumn 22, Issue 3, 2003, Pages 236-240

  Labarrere, Carlos A ^a   Nelson, David R ^b   Spear, Karen L ^a  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTITHROMBIN; ARGININE; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SERINE PROTEINASE INHIBITOR; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN;

ANGIOGENESIS; CARDIOVASCULAR RISK; CELL DAMAGE; CELL DEATH; CORONARY ARTERY DISEASE; DISEASE COURSE; GENE TRANSFER; GRAFT FAILURE; GRAFT SURVIVAL; HEART MUSCLE CELL; HEART TRANSPLANTATION; MICROVASCULATURE; PRIORITY JOURNAL; REVIEW; SURVIVAL; THROMBOGENICITY; VASCULAR ENDOTHELIUM;

CORONARY DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; MICROCIRCULATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037336293     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00669-1     Document Type: Review

References (37)

1. Martin J. The idea is more important than the experiment. Lancet. 356:2000;934-937.
2. Harlan D.M., Kirk A.D. The future of organ and tissue transplantation. Can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA. 282:1999;1076-1082.
3. Faulk W.P., Labarrere C.A., Pitts D., Halbrook H. Vascular lesions in biopsy specimens devoid of cellular infiltrates qualitative and quantitative immunocytochemical studies of human cardiac allografts. J Heart Lung Transplant. 12:1993;219-229.
4. Murray M.J., Lessey B.A. Embryo implantation and tumor metastasis common pathways of invasion and angiogenesis. Semin Reprod Endocrinol. 17:1999;275-290.
5. Labarrere C.A., Nelson D.R., Park J.-W. Pathologic markers of allograft arteriopathy insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol. 16:2001;110-117.
6. Labarrere C.A., Pitts D., Nelson D.R., Faulk W.P. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med. 333:1995;1111-1116.
7. Labarrere C.A., Nelson D.R., Faulk W.P. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA. 278:1997;1169-1175.
8. Labarrere C.A., Nelson D.R., Faulk W.P. Myocardial fibrin deposits in the first month after transplantation predicts subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med. 105:1998;207-213.
9. Labarrere C.A. Relationship of fibrin deposition in microvasculature to outcomes in cardiac transplantation. Curr Opin Cardiol. 14:1999;133-139.
10. Labarrere C.A., Torry R.J., Nelson D.R., et al. Vascular antithrombin and clinical outcome in heart transplant patients. Am J Cardiol. 87:2001;425-431.
11. Johnson D.E., Gao S.Z., Schroeder J.S., DeCampli W.M., Billingham M.E. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant. 8:1989;349-359.
12. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography a multi-institutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant. 17:1998;744-753.
13. Labarrere C.A., Nelson D.R., Miller S.J., et al. Value of serum soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events and cardiac graft failure. Circulation. 102:2000;1549-1555.
14. Labarrere C.A., Nelson D.R., Cox C.J., Pitts D., Kirlin P., Halbrook H. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA. 284:2000;457-464.
15. Mehra M.R., Ventura H.O., Chambers R.B., Ramireddy K., Smart F.W., Stapleton D.D. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy time for a reappraisal. J Heart Lung Transplant. 16:1997;743-751.
16. Marboe C.C. Cardiac transplant vasculopathy. Major Probl Pathol. 30:1994;111-132.
17. Hosenpud J.D., Shipley G.D., Wagner C.R. Cardiac allograft vasculopathy current concepts, recent developments, and future directions. J Heart Lung Transplant. 11:1992;9-23.
18. + T cells to differentiate into CTL retaining an early activation phenotype. J Immunol. 164:2000;5146-5155.
19. Rose E.A., Pepino P., Barr M.L., et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant. 11:(suppl):1992;S120-123.
20. McIntyre J.A., Wagenknecht D.R., Faulk W.P. Antiphospholipid antibodies in heart transplant recipients. Clin Cardiol. 18:1995;575-580.
21. Dunn M.J., Crisp S.J., Rose M.L., Taylor P.M., Yacoub M.H. Antiendothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 339:1992;1566-1570.
22. Crisp S.J., Dunn M.J., Rose M.L., Barbir M., Yacoub M.H. Antiendothelial antibodies after heart transplantation the accelerating factor in transplant-associated coronary artery disease? J Heart Lung Transplant. 13:1994;81-92.
23. Russell P.S., Chase C.M., Winn J.H., Colvin R.B. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol. 152:1994;5135-5141.
24. Torry R.J., Labarrere C.A., Torry D.S., Holt V.J., Faulk W.P. Vascular endothelial growth factor expression in transplanted human hearts. Transplantation. 60:1995;1451-1457.
25. Torry R.J., Bai L., Miller S.J., Labarrere C.A., Nelson D., Torry D.S. Increased vascular endothelial growth factor expression in human hearts with microvascular fibrin. J Mol Cell Cardiol. 33:2001;175-184.
26. Szabo G., Bahrle S., Batkai S., et al. L-arginine effect on reperfusion injury after heart transplantation. World J Surg. 22:1998;791-798.
27. Ostrovsky L., Woodman R.C., Payne D., Teoh D., Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. 96:1997;2302-2310.
28. Jaeger B.R., Meiser B., Nagel D., et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation. 96:(supplII):1997;II154-158.
29. Park J.W., Merz M., Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant. 16:1997;290-297.
30. Teranishi K., Poston R.S., Reitz B.A., Robbins R.C. Effect of low molecular weight heparin on suppression of chronic graft vascular disease in a rat cardiac allograft model. Transplant Proc. 30:1998;1009-1011.
31. Scholl F.G., Sen L., Drinkwater D.C., et al. Effects of human tissue plasminogen activator gene transfer on allograft coronary atherosclerosis. J Heart Lung Transplant. 20:2001;322-329.
32. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
33. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation a four-year randomized trial. Circulation. 96:1997;1398-1402.
34. Suzuki J., Isobe M., Yamazaki S., Horie S., Okubo Y., Sekiguchi M. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. J Heart Lung Transplant. 16:1997;1141-1148.
35. Suzuki J., Isobe M., Morishita R., et al. Antisense Cdk2 kinase oligodeoxynucleotide inhibits ICAM-1 expression in murine cardiac allograft arteriopathy. Transplant Proc. 30:1998;89-90.
36. 165 in patient with ischaemic limb. Lancet. 348:1996;370-374.
37. Losordo D.W., Vale P.R., Isner J.M. Gene therapy for myocardial angiogenesis. Am Heart J. 138:(suppl):1999;S132-141.